Can open-source R&D reinvigorate drug research?

Nature Reviews Drug Discovery

Volumn 5, Issue 9, 2006, Pages 723-729

  Munos, Bernard ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; BCG VACCINE; BENFLUMETOL; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CONTRACEPTIVE AGENT; CYSTEINE PROTEINASE INHIBITOR; DAPSONE; DENGUE VACCINE; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE INHIBITOR; DIPYRONE; EUARTEKIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISONIAZID DERIVATIVE; MALARIA VACCINE; MILTEFOSINE; MOXIFLOXACIN; PAROMOMYCIN; PIPERAQUINE; PNEUMOCOCCUS VACCINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRIDONE DERIVATIVE; PYRONARIDINE; QUINOLIZINE DERIVATIVE; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOINFORMATICS; BUDGET; COMPUTER PROGRAM; DENGUE; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; GOOD CLINICAL PRACTICE; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HUMAN; INTERNET; MALARIA; MANAGEMENT; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TUBERCULOSIS; UNITED STATES;

CLINICAL TRIALS; DATABASES, FACTUAL; DRUG APPROVAL; DRUG DESIGN; HUMANS; ORGANIZATIONAL INNOVATION; RESEARCH; SOFTWARE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748324666     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2131     Document Type: Article

References (19)

1. Hollingsworth, J. R. & Hollingsworth, E. J. in Practicing Interdisciplinarity (eds Weingart, P. & Stehr, N.) 215-244 (Univ. Toronto Press, Toronto, 2000).
2. Hollingsworth, J. R. in Creating a Tradition of Biomedical Research (ed. Stapleton, D.) 17-63 (Rockefeller Univ. Press, New York, 2004).
3. Feldman, R. The open-source biotechnology movement: Is it patent misuse? Minn. J. L. Sci. Tech. 6, 1 (2004).
4. Cukier, K. N. Community property: Open-source proponents plant the seeds of a new patent landscape. Acumen 1, 54-60 (2003).
5. Rai, A. Open and collaborative research: A new model for biomedicine. Duke Law School, Legal Studies Research Paper Series, Research Paper 61 (2004).
6. Maurer, S. New institutions for doing science: From databases to open biology. Presented at University of Maastricht, November 24-25 (2003).
7. DeLano, W. L., The case for open-source software in drug discovery. Drug Discov. Today 10, 213-217 (2005).
8. Geldenhuys, W. J., Gaasch, K. E., Watson, M., Allen, D. D. & Van der Schyf, C. J. Optimizing the use of open-source software applications in drug discovery. Drug Discov Today 11, 127-132 (2006).
9. Eisenmenger, F., Hansmann, U. H. E., Hayryan, S. & Hu, C. An enhanced version of SMMP - open-source software package for simulation of proteins. Computer Phys. Comm. 174, 422-429 (2006).
10. An open-source shot in the arm. The Economist (12 June 2004).
11. DeMonaco, H. J., Ali, A. & Von Hippel, E. The major role of clinicians in the discovery of off-label drug therapies. MIT Sloan Working Paper 4552-05 (2005).
12. Maurer, S. M., Rai, A. & Sali A. finding cures for tropical diseases: Is open-source the answer? PLoS Med. 1, e56 (2004).
13. Gardner, C. & Garner, C. Technology Licensing to nontraditional partners: Non-profit health product development organizations for better global health. Industry Higher Education 19, 241-247 (2005).
14. DeBresson, C. & Amesse, F. Networks of innovators: A review and introduction to the issue. Res. Policy 20, 363-379 (1991).
15. Nwaka, S. & Ridley, R. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919-928 (2003).
16. Hope, J. Open-Source Biotechnology. Ph.D. Thesis, Australian National Univ. (2004).
17. Stahl, M. T. Open-source software: Not quite endsville. Drug Discov. Today 10, 219-222 (2005).
18. Collins, F. S. The NIH Roadmap: New pathways to discovery - empowering small molecule research. Office of Portfolio Analysis and Strategic Initiatives (National Institutes of Health, Bethesda, 2006).
19. Towse, A. & Renowden, O. in Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships (eds Widdus, R. & White, K.) [online], Initiative on Public-Private Partnerships for Health, London, 2004).